摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-amino-piperidin-1-yl)-benzamide | 1039022-14-4

中文名称
——
中文别名
——
英文名称
2-(4-amino-piperidin-1-yl)-benzamide
英文别名
2-(4-Aminopiperidin-1-yl)benzamide
2-(4-amino-piperidin-1-yl)-benzamide化学式
CAS
1039022-14-4
化学式
C12H17N3O
mdl
MFCD12137450
分子量
219.286
InChiKey
BDWRGCPAYZUTLE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.416
  • 拓扑面积:
    72.4
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses
    摘要:
    Further investigation of the recently reported piperidine-4-yl-aminopyrimidine class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out. Thus, preparation of a series of N-phenyl piperidine analogs resulted in the identification of 3-carboxamides as a particularly active series. Analogs such as 28 and 40 are very potent versus wild-type HIV-1 and a broad range of NNRTI-resistant mutant viruses. Synthesis, structure-activity relationship (SAR), clearance data, and crystallographic evidence for the binding motif are discussed. (c) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.08.068
  • 作为产物:
    描述:
    三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 生成 2-(4-amino-piperidin-1-yl)-benzamide
    参考文献:
    名称:
    Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses
    摘要:
    Further investigation of the recently reported piperidine-4-yl-aminopyrimidine class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out. Thus, preparation of a series of N-phenyl piperidine analogs resulted in the identification of 3-carboxamides as a particularly active series. Analogs such as 28 and 40 are very potent versus wild-type HIV-1 and a broad range of NNRTI-resistant mutant viruses. Synthesis, structure-activity relationship (SAR), clearance data, and crystallographic evidence for the binding motif are discussed. (c) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.08.068
点击查看最新优质反应信息

文献信息

  • Non-nucleoside reverse transcriptase inhibitors
    申请人:Kestesz Denis John
    公开号:US20080146595A1
    公开(公告)日:2008-06-19
    The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
    本发明提供了用于治疗HIV感染、预防HIV感染、治疗AIDS或ARC的化合物。本发明的化合物具有如下式I所示的结构,其中R1、R2、R3、R4、R5a、R5b、R6a、R6b和X的定义如本文所述。本发明还公开了使用上述定义的化合物治疗HIV感染的方法,以及含有这些化合物的药物组合物。
  • PIM KINASE INHIBITORS AND METHODS OF THEIR USE
    申请人:Burger Matthew
    公开号:US20120208815A1
    公开(公告)日:2012-08-16
    New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    提供了一种用于抑制人或动物主体中与肿瘤发生相关的激酶活性的新化合物、组合物和方法。在某些实施例中,这些化合物和组合物能够有效地抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。这些新的化合物和组合物可以单独使用或与至少一种额外的药物联合使用,用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的疾病,如癌症。
  • 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
    申请人:F. Hoffmann-La Roche AG
    公开号:EP2089384B1
    公开(公告)日:2015-08-05
  • US7998969B2
    申请人:——
    公开号:US7998969B2
    公开(公告)日:2011-08-16
  • US8822497B2
    申请人:——
    公开号:US8822497B2
    公开(公告)日:2014-09-02
查看更多